TRL-345 by Trellis Bioscience for Cytomegalovirus (HHV-5) Infections: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TRL-345 overview

TRL-345 (CMV-345) is under development for the treatment of human cytomegalovirus infections. The drug candidate acts by targeting HCMV glycoprotein B (gB). It is developed based on the CellSpot technology. It is administered through intravenous route.

Trellis Bioscience overview

Trellis Bioscience (Trellis), formerly Trellis Bioscience, is a drug development company that discovers and develops human antibody therapeutics for the treatment of bacterial and viral infectious diseases and cancer indications. Its clinical candidate includes TRL1068, which targets and disintegrates bacterial biofilm. The company develops CellSpot technology to find rare human antibodies that are identified and recovered from human blood cells. Its antibodies can be applied in the treatment of infectious disease such as respiratory syncytial virus, cytomegalovirus, auto-immune diseases, Influenza and cancer. The company provides pipeline of therapies in bacterial, viral, and cancer indications. It operates through government and philanthropic institutions, biotech and pharma companies. Trellis is headquartered in Menlo Park, California, the US.

For a complete picture of TRL-345’s drug-specific PTSR and LoA scores, buy the report here.

Sign up for our daily news round-up!

Give your business an edge with our leading industry insights.